A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
CB307 is a trispecific Humabody® targeting CD137; PSMA; and human serum albumin (HSA)
undergoing Phase 1 assessment in patients with PSMA+ solid tumours. This sub study will
assess the biodistribution of radiolabelled CB307 in patients with advanced and/or metastatic
solid tumours that are PSMA+.